leadf
logo-loader
viewInnovaDerma PLC

InnovaDerma PLC - Quality is more than skin deep

InnovaDerma (LON:IDP) specialises in the development, manufacture and marketing of clinically proven products in life sciences, beauty, and personal care. The company operates a portfolio of strong innovative brands, reaching customers in the UK and Australia, and increasingly in North America, Asia, and EU.

Executive summary

The company listed on the LSE main board in 2016 and has delivered revenue CAGR (compound annualised growth rate) of 58% and earnings per share (EPS) CAGR of 31% in its first two years (to June 2018e).
InnovaDerma reported full-year results to June 2018 on September 19. These were in line with market expectations, with 21% like-for-like revenue growth. In this report, we focus on the drivers going forward.

Quick facts: InnovaDerma PLC

Price: 60 GBX

LSE:IDP
Market: LSE
Market Cap: £8.7 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnovaDerma PLC named herein, including the promotion by the Company of InnovaDerma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

InnovaDerma reports strong cash and 'resilient performance' during pandemic

InnovaDerma PLC's (LON:IDP) chairman Joe Bayer and CEO Kieran Callan tell Proactive London's Andrew Scott the business has performed resiliently during the coronavirus pandemic lockdown but have been hit by rising advertising costs. Bayer says they now want to start swinging the earnings...

on 13/7/20

13 min read